Skip to main content

Advertisement

SpringerLink
Log in

Functional heartburn

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Functional heartburn (FH) is a common disorder that accounts for 30% to 50% of the patients with nonerosive reflux disease. FH is composed from a heterogeneous group of patients. They primarily include the hypersensitive and the nonacid sensitive esophagus. The mechanisms responsible for pain, clinical characteristics, and the optimal therapeutic approach of FH remain to be fully elucidated. Symptom response rate to potent antireflux treatment is significantly lower in FH patients as compared with any other gastroesophageal reflux disease (GERD) group, suggesting that in proton pump inhibitor (PPI) non-responders mechanisms other than acid reflux are likely the cause of symptoms. Patients with FH should be approached therapeutically as patients with GERD and should initially receive antireflux medications. Due to the need for profound acid suppression in this group of patients, PPIs should be considered relatively early in their care. Failure to respond to standard dosage of PPI is common and will require doubling the dose. If patients continue to report heartburn symptoms while receiving PPI twice daily, adding or switching to pain modulators/visceral analgesics is an appropriate therapeutic approach. Data about the usage of other therapeutic modalities in FH such as antireflux surgery, endoscopic treatment for GERD, and psychotherapy are still unavailable. Emerging treatment will likely include novel pain modulators and more effective antireflux medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fass R, Tougas G: Functional heartburn: the stimulus, the pain, and the brain. Gut 2002, 51: 885–892. A very important paper that summarizes in detail the pathophysiology, clinical presentation and treatment of functional heartburn.

    Article  PubMed  CAS  Google Scholar 

  2. Klinkenberg-Knol EC, Castell DO: Clinical spectrum and diagnosis of gastroesophageal reflux disease. In The Esophagus. 3rd ed. Castell DO, Richter JE, editors. Philadelphia: Lippincott Williams and Wilkins 1999, 75–380.

    Google Scholar 

  3. Lind T, Havelund T, Carlsson R: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997, 32: 974–979. An important paper that describes the symptom response rate of functional heartburn patients to PPI therapy as compared to NERD patients with abnormal pH values.

    Article  PubMed  CAS  Google Scholar 

  4. Jones RH, Hungin ADS, Phillips J: Gastroesophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur J Gen Pract 1995, 1: 14–154.

    Article  Google Scholar 

  5. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997, 92: 1997–2000.

    PubMed  CAS  Google Scholar 

  6. Johnsson F, Weywadt L, Solhaug JH, et al.: One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998, 33: 15–20.

    Article  PubMed  CAS  Google Scholar 

  7. Fass R, Ofman JJ, Gralnek IM, Johnson C, et al.: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999, 159: 2161–2168.

    Article  PubMed  CAS  Google Scholar 

  8. Mayer E, Naliboff B, Lee O, Munakata J, Chang L: Review article: gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther 1999, 13: 65–69.

    Article  PubMed  Google Scholar 

  9. Martinez SD, Malagon IB, Garewal HS, et al.: Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003, 17: 537–545. A paper that describes the acid reflux characteristics of the different sub-groups of NERD.

    Article  PubMed  CAS  Google Scholar 

  10. Weiner GJ, Morgan TM, Copper JB, et al.: The symptom index: A clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988, 83: 358–361.

    Google Scholar 

  11. Meyer JH, Lembo A, Elashoff JD, et al.: Duodenal fat intensifies the perception of heartburn. Gut 2001, 49: 624–628.

    Article  PubMed  CAS  Google Scholar 

  12. Waring JP: Nonerosive reflux disease. Semin Gastrointest Dis 2001, 12: 33–37.

    PubMed  CAS  Google Scholar 

  13. Fass R, Naliboff B, Higa L, et al.: Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998, 115: 1363–1373.

    Article  PubMed  Google Scholar 

  14. Hobson AR, Matthews P, Furlong P, Aziz Q: The role of esophageal afferent pathway sensitivity in non-erosive reflux disease (abstract). Gastroenterology 2004, 126: A-18, 128.

    Google Scholar 

  15. Rodriguez-Stanley S, Robinson M, Earnest DL, et al.: Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol 1999, 94: 628–631.

    Article  PubMed  CAS  Google Scholar 

  16. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB, Jr: Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005, 50: 81–85.

    Article  PubMed  Google Scholar 

  17. Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995, 37: 7–12.

    PubMed  CAS  Google Scholar 

  18. Schindlbeck NE, Wiebecke B, Klauser AG, et al.: Diagnostic value of histology in non-erosive gastrooesophageal reflux disease. Gut 1996, 39: 151–154.

    PubMed  CAS  Google Scholar 

  19. Frazzoni M, De Micheli E, Zentilin P, Savarino V: Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004, 20: 81–88.

    Article  PubMed  CAS  Google Scholar 

  20. Watson RG, Tham TC, Johnston BT, McDougall NI: Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive esophagus". Gut 1997, 40: 587–590.

    PubMed  CAS  Google Scholar 

  21. Richter JE, Campbell DR, Kahrilas PJ, et al.: Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000, 160: 1803–1809.

    Article  PubMed  CAS  Google Scholar 

  22. Fass R, Murthy U, Hayden CW, et al.: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-esophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000, 14: 1595–1603.

    Article  PubMed  CAS  Google Scholar 

  23. Fass R, Quan SF, O’Connor GT, et al.: Predictors of heartburn during sleep in a large prospective cohort study. Chest 2005, 127: 1658–1666.

    Article  PubMed  Google Scholar 

  24. Marrero JM, de Caestecker JS, Maxwell JD: Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. Gut 1994, 35: 447–450.

    PubMed  CAS  Google Scholar 

  25. Rodriguez-Stanley S, Ciociola AA, Zubaidi S, et al.: A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn. Aliment Pharmacol Ther 2004, 20: 975–982.

    Article  PubMed  CAS  Google Scholar 

  26. Clouse RE, Lustman PJ, Eckert TC, et al.: Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987, 92: 1027–1036.

    PubMed  CAS  Google Scholar 

  27. Cannon RO, 3rd, Quyyumi AA, Mincemoyer R, et al.: Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994, 330: 1411–1417.

    Article  PubMed  Google Scholar 

  28. Fenton P, Terry ML, Galloway KD, et al.: Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD)? (abstract). Gastroenterology 2000, 18: A481, 2600.

    Google Scholar 

  29. Sarkar S, Aziz Q, Woolf CJ, et al.: Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000, 356: 1154–1159.

    Article  PubMed  CAS  Google Scholar 

  30. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ: The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000, 14: 1503–1509.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GI Section (1-111G-1), Southern Arizona VA Health Care System, 3601 South 6th Avenue, Tucson, 85723-0001, Arizona, USA

    Ronnie Fass MD

Authors
  1. Ram Dickman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronnie Fass MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dickman, R., Fass, R. Functional heartburn. Curr Treat Options Gastro 8, 285–291 (2005). https://doi.org/10.1007/s11938-005-0021-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-005-0021-0

Keywords

Search

Navigation